Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 2
1995 2
1996 8
1997 5
1998 7
1999 5
2000 2
2001 3
2002 7
2003 7
2004 7
2005 10
2006 20
2007 17
2008 11
2009 16
2010 21
2011 24
2012 36
2013 36
2014 52
2015 73
2016 95
2017 126
2018 170
2019 221
2020 277
2021 383
2022 449
2023 453
2024 201

Text availability

Article attribute

Article type

Publication date

Search Results

2,483 results

Results by year

Filters applied: . Clear all
Page 1
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP, Tang XY, Xiong YL, Zheng KF, Liu YJ, Shi XG, Lv Y, Jiang T, Ma N, Zhao JB. Shi AP, et al. Front Immunol. 2022 Jan 17;12:785091. doi: 10.3389/fimmu.2021.785091. eCollection 2021. Front Immunol. 2022. PMID: 35111155 Free PMC article. Review.
LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. ...This review comprises four sections presenting the structure/expression, interaction, biological effects, and clinical application of LAG3/FGL1. D1 and D2 of LAG3 and FD of FGL1 are the …
LAG3 is the most promising immune checkpoint next to PD-1 and CTLA-4. ...This review comprises four sections presenting the structure …
LAG3's Enigmatic Mechanism of Action.
Graydon CG, Mohideen S, Fowke KR. Graydon CG, et al. Front Immunol. 2021 Jan 8;11:615317. doi: 10.3389/fimmu.2020.615317. eCollection 2020. Front Immunol. 2021. PMID: 33488626 Free PMC article. Review.
We also discuss the interactions of LAG3 with its ligands and the purpose thereof. Finally, we review LAG3's mechanism of action, including the roles of LAG3 intracellular motifs and the lack of a role for CD4 competition. Overall, understanding the biology o …
We also discuss the interactions of LAG3 with its ligands and the purpose thereof. Finally, we review LAG3's mechanism of acti …
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Ruffo E, et al. Semin Immunol. 2019 Apr;42:101305. doi: 10.1016/j.smim.2019.101305. Semin Immunol. 2019. PMID: 31604537 Free PMC article. Review.
Persistent antigen-stimulation in cancer or chronic infection leads to chronic LAG3 expression, promoting T cell exhaustion. Targeting LAG3 along with PD1 facilitates T cell reinvigoration. ...In this review, we will discuss the structure, function and role of LA …
Persistent antigen-stimulation in cancer or chronic infection leads to chronic LAG3 expression, promoting T cell exhaustion. Targetin …
LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation.
Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. Guy C, et al. Nat Immunol. 2022 May;23(5):757-767. doi: 10.1038/s41590-022-01176-4. Epub 2022 Apr 18. Nat Immunol. 2022. PMID: 35437325 Free PMC article.
LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function remains unclear. ...
LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-targeting immunotherapeutics are c …
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q, Celias DP, Wu C, Cole AR, Singh S, Mason C, Dong S, Tran TH, Amarasinghe GK, Ruffell B, Luca VC. Ming Q, et al. Nat Immunol. 2022 Jul;23(7):1031-1041. doi: 10.1038/s41590-022-01238-7. Epub 2022 Jun 27. Nat Immunol. 2022. PMID: 35761082 Free PMC article.
We also defined the LAG3-FGL1 interface by mapping mutations onto structures of LAG3 and FGL1 and established that FGL1 cross-linking induces the formation of higher-order LAG3 oligomers. These insights can guide LAG3-based drug development and implica …
We also defined the LAG3-FGL1 interface by mapping mutations onto structures of LAG3 and FGL1 and established that FGL1 cross- …
LAG3 (CD223) and autoimmunity: Emerging evidence.
Hu S, Liu X, Li T, Li Z, Hu F. Hu S, et al. J Autoimmun. 2020 Aug;112:102504. doi: 10.1016/j.jaut.2020.102504. Epub 2020 Jun 20. J Autoimmun. 2020. PMID: 32576412 Review.
Its unique intracellular domains, signaling patterns as well as the striking synergy observed in its targeted therapy with anti-PD1 indicate the important role of LAG3 in maintaining immune tolerance. Currently, a variety of agents targeting LAG3 are in clinical tri …
Its unique intracellular domains, signaling patterns as well as the striking synergy observed in its targeted therapy with anti-PD1 indicate …
Lag3: From Bench to Bedside.
Aroldi F, Saleh R, Jafferji I, Barreto C, Saberian C, Middleton MR. Aroldi F, et al. Cancer Treat Res. 2022;183:185-199. doi: 10.1007/978-3-030-96376-7_6. Cancer Treat Res. 2022. PMID: 35551660 Review.
LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP, Marciscano AE, Drake CG, Vignali DA. Andrews LP, et al. Immunol Rev. 2017 Mar;276(1):80-96. doi: 10.1111/imr.12519. Immunol Rev. 2017. PMID: 28258692 Free PMC article. Review.
LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity. ...The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remain largely unknown. However, the striking synergy between LAG3 and PD1 obser …
LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity. ...The exact signaling mechanisms do …
LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis.
Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, Ganal-Vonarburg SC, Wilson DC, McClanahan TK, Malefyt RW, Macpherson AJ, Annamalai L, Yearley JH, Cua DJ. Bauché D, et al. Immunity. 2018 Aug 21;49(2):342-352.e5. doi: 10.1016/j.immuni.2018.07.007. Epub 2018 Aug 7. Immunity. 2018. PMID: 30097293 Free article.
2,483 results